Schrodinger Inc. (SDGR) News

Schrodinger Inc. (SDGR): $17.42

-0.07 (-0.40%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter SDGR News Items

SDGR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SDGR News Highlights

  • For SDGR, its 30 day story count is now at 10.
  • Over the past 20 days, the trend for SDGR's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about SDGR are AMP and ASH.

Latest SDGR News From Around the Web

Below are the latest news stories about SCHRODINGER INC that investors may wish to consider to help them evaluate SDGR as an investment opportunity.

Down More Than 40%: Analysts See an Appealing Entry Point in These 2 ‘Strong Buy’ Stocks

It’s difficult to put a positive spin on the current state of the stock market. While 2022’s action has seen moments of relief, for the most part, the trend has been resolutely downbeat, as reflected in the main indexes’ performances. All are down by at least double-digits; the tech-heavy NASDAQ’s 30% drop has been the most acute, while the S&P 500 now sits 17% lower year-to-date. That said, while it’s hard to watch any owned stock sink to the bottom, the upside to the downside is that investors get to pick up shares of good companies on the cheap.

Michael Marcus on TipRanks | November 22, 2022

Schrödinger to Present at Piper Sandler 34th Annual Healthcare Conference

NEW YORK, November 21, 2022--Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference. The presentation will take place on Tuesday, November 29, 2022, at 4:00 p.m. ET.

Yahoo | November 21, 2022

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, November 18, 2022--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on November 15, 2022, the company granted non-statutory stock options to purchase an aggregate of 32,165 shares of the company’s common stock to eight newly hired employees, including two newly hired employees based outside of the United States. These grants were made pursuant to the company’s 2021 Inducem

Yahoo | November 18, 2022

Schrödinger Third Quarter 2022 Earnings: Beats Expectations

Schrödinger ( NASDAQ:SDGR ) Third Quarter 2022 Results Key Financial Results Revenue: US$37.0m (up 24% from 3Q 2021...

Yahoo | November 9, 2022

Schrödinger to Present at Jefferies 13th Annual London Healthcare Conference

NEW YORK, November 07, 2022--Schrödinger today announced that management will participate in the Jefferies 13th Annual London Healthcare Conference in London, UK.

Yahoo | November 7, 2022

3 Hypergrowth Stocks That Will Make You a Millionaire by 2027

These companies' great third-quarter results, along with their very promising technologies, are likely to turn them into hypergrowth stocks.

Larry Ramer on InvestorPlace | November 4, 2022

Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates

Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 8.20% and 14.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 3, 2022

Schrödinger Reports Third Quarter 2022 Financial Results

NEW YORK, November 03, 2022--Schrödinger today reported financial results for the third quarter of 2022 and provided an update on the company.

Yahoo | November 3, 2022

Schrödinger To Present New Preclinical Data From Its CDC7 Inhibitor Program At American Society Of Hematology 2022 Annual Meeting

NEW YORK, November 03, 2022--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new preclinical data on its CDC7 inhibitor, SGR-2921, will be presented during a poster session at the American Society of Hematology (ASH) 64th Annual Meeting taking place virtually and in New Orleans, Louisiana, December 10-13, 2022.

Yahoo | November 3, 2022

The 7 Best Stocks to Buy on a Dip

For investors looking for the best stocks to buy on a dip, “the dip” can mean a lot of different things. It can be the case of a market dominator that is trading near its low following a brutal bear market. Or it can be a stock that has bounced recently following an extended downtrend, thus signaling that shares may have bottomed. It could even be a stock that has defied the broader market to deliver a stellar performance in 2022. In the latter case, even a modest pullback may offer a chance to

Yahoo | November 2, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6815 seconds.